Skip to main content

Identification of Ovarian Cancer Stem Cells: Molecular Pathways

  • Chapter
  • First Online:
Stem Cells and Cancer Stem Cells, Volume 11

Part of the book series: Stem Cells and Cancer Stem Cells ((STEM,volume 11))

  • 1293 Accesses

Abstract

Ovarian cancer is one of the major causes of cancer-related deaths among the female reproductive tract cancers worldwide. The foremost problem with ovarian cancer is in its heterogeneity, different subtypes and drug resistance. Moreover, the different types of ovarian cancer, such as endometrioid, serous, clear cell and mucinous appends to the complexity of this cancer. These tumors contain a small population of cells known as cancer stem cells (CSCs), which have the capacity to self-renew and are highly drug resistant, leading to tumor relapse. CSCs have attained tremendous attention in the last decade and have been shown to be a major target in various cancers including ovarian cancer. Understanding the molecular pathways implicated by ovarian CSCs is crucial to combat the residual disease following chemotherapy and combinational therapies. Several markers, such as CD24, CD44, CD117, CD133 and ALDH1, are found to be highly expressed on the surface of ovarian CSCs and can be used as a target as well as to battle ovarian cancer. This book chapter focuses on CSCs and their associate molecules and molecular pathways involved in the maintenance of ovarian CSCs, specific targets and the novel therapeutic implications of ovarian CSCs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Aguilar-Gallardo C, Rutledge EC, Martinez-Arroyo AM, Hidalgo JJ, Domingo S, Simon C (2012) Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev 8(3):994–1010

    Article  PubMed  CAS  Google Scholar 

  • Bapat SA (2010) Human ovarian cancer stem cells. Reproduction 140(1):33–41

    Article  PubMed  CAS  Google Scholar 

  • Chau WK, Ip CK, Mak AS, Lai HC, Wong AS (2012) c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 10. doi:10.1038/onc.2012.290

  • Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, Lum L (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5(2):100–107

    Article  PubMed  CAS  Google Scholar 

  • Choi JH, Park JT, Davidson B, Morin PJ, Shih I, Wang TL (2008) Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 68(14):5716–5723

    Article  PubMed  CAS  Google Scholar 

  • De Sousa EM, Vermeulen L, Richel D, Medema JP (2011) Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 17(4):647–653

    Article  PubMed  Google Scholar 

  • Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Butzow R, Coukos G, Zhang L (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5(4):e10277

    Article  PubMed  Google Scholar 

  • Dyall S, Gayther SA, Dafou D (2010) Cancer stem cells and epithelial ovarian cancer. J Oncol 2010:105269

    Article  PubMed  Google Scholar 

  • Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G (2009) CD133 antigen expression in ovarian cancer. BMC Cancer 9:221

    Article  PubMed  Google Scholar 

  • Gamallo C, Palacios J, Moreno G, de Calvo MJ, Suarez A, Armas A (1999) beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155(2):527–536

    Article  PubMed  CAS  Google Scholar 

  • Gao MQ, Choi YP, Kang S, Youn JH, Cho NH (2010) CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29(18):2672–2680

    Article  PubMed  CAS  Google Scholar 

  • Hadden MK (2013) Hedgehog pathway inhibitors: a patent review (2009 – present). Expert Opin Ther Pat 23(3):345–361

    Article  PubMed  CAS  Google Scholar 

  • Hopfer O, Zwahlen D, Fey MF, Aebi S (2005) The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 93(6):709–718

    Article  PubMed  CAS  Google Scholar 

  • Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, Hwang YY, An HJ (2010) Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci 101(9):1977–1983

    Article  PubMed  CAS  Google Scholar 

  • Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM (2012) High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 109(10):3921–3926

    Article  PubMed  CAS  Google Scholar 

  • Koh J, Lee SB, Park H, Lee HJ, Cho NH, Kim J (2012) Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells. Biochem Biophys Res Commun 427(2):373–378

    Article  PubMed  CAS  Google Scholar 

  • Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30(19):2307–2313

    Article  PubMed  CAS  Google Scholar 

  • Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186–3199

    Article  PubMed  CAS  Google Scholar 

  • Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH (2003) beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 88(3):363–368

    Article  PubMed  CAS  Google Scholar 

  • Lin TL, Matsui W (2012) Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther 5:47–58

    Article  PubMed  CAS  Google Scholar 

  • Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, Guichet PO, Bian X, Armesilla AL, Darling JL, Wang W (2012) Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 107(9):1488–1497

    Article  PubMed  CAS  Google Scholar 

  • LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD (2011) Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17(8):2502–2511

    Article  PubMed  CAS  Google Scholar 

  • Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G (2008) Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 113(4):723–732

    Article  PubMed  CAS  Google Scholar 

  • McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J Jr, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM (2012) Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 109(43):E2939–E2948

    Article  PubMed  CAS  Google Scholar 

  • Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18(4):260–267

    Article  PubMed  CAS  Google Scholar 

  • Platt VM, Szoka FC Jr (2008) Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5(4):474–486

    Article  PubMed  CAS  Google Scholar 

  • Ponnusamy MP, Batra SK (2008) Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res 1(1):4

    Article  PubMed  Google Scholar 

  • Raspollini MR, Amunni G, Villanucci A, Baroni G, Taddei A, Taddei GL (2004) c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann Oncol 15(4):594–597

    Article  PubMed  CAS  Google Scholar 

  • Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434(7035):843–850

    Article  PubMed  CAS  Google Scholar 

  • Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J (2010) Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol 23(1):113–122

    Article  PubMed  CAS  Google Scholar 

  • Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, Clevers H (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337(6095):730–735

    Article  PubMed  CAS  Google Scholar 

  • Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC (2008) Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 26(20):3418–3425

    Article  PubMed  CAS  Google Scholar 

  • Shan J, Shi DL, Wang J, Zheng J (2005) Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 44(47):15495–15503

    Article  PubMed  CAS  Google Scholar 

  • Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL, Moore PA, Ruben SM, Carter PJ (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99(1):100–109

    Article  PubMed  CAS  Google Scholar 

  • Su D, Deng H, Zhao X, Zhang X, Chen L, Chen X, Li Z, Bai Y, Wang Y, Zhong Q, Yi T, Qian Z, Wei Y (2009) Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy 11(5):642–652

    Article  PubMed  CAS  Google Scholar 

  • Szkandera J, Kiesslich T, Haybaeck J, Gerger A, Pichler M (2013) Hedgehog signaling pathway in ovarian cancer. Int J Mol Sci 14(1):1179–1196

    Article  PubMed  CAS  Google Scholar 

  • Taipale J, Beachy PA (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature 411(6835):349–354

    Article  PubMed  CAS  Google Scholar 

  • Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ (2012) Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30(19):2348–2353

    Article  PubMed  CAS  Google Scholar 

  • Yan M (2011) Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell 3:17

    Article  PubMed  CAS  Google Scholar 

  • Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68(11):4311–4320

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

 The authors on this book chapter were supported by the grant from the Elsa U Pardee Foundation (2013).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Moorthy P. Ponnusamy .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Vaz, A.P., Seshacharyulu, P., Batra, S.K., Ponnusamy, M.P. (2014). Identification of Ovarian Cancer Stem Cells: Molecular Pathways. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells, Volume 11. Stem Cells and Cancer Stem Cells, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7329-5_15

Download citation

Publish with us

Policies and ethics